Introduction
In 1969 Hellstrom and Hellstroml showed the ability of sera from tumour-bearing animals to block cell-mediated immunity in vitro. Subsequently, these "blocking factors" have been found in various experimental animal tumours and also in the sera of patients with cancer. 2 The observation that blocking factors disappeared rapidly after spontaneous regression or excision in both experimental animal systems and malignancies' 1 suggested that tumour-specific immune complexes may be implicated in this phenomenon. Thus in animals or patients rendered tumour free tumour-specific antigens are eliminated and antibody activity becomes demonstrable. Evidence to support the immune-complex nature of blocking activity has been provided in several animal studies,;7 which suggests that tumour-specific antigen-antibody complexes play a biologically important part in the control of tumour growth.
In 1973 We describe here evidence that the measurement of soluble circulating immune complexes by radioimmunoprecipitation with '25I-Clq may help in determining the prognosis of individual patients with primary operable breast cancer and in monitoring the course of the disease.
Patients and methods
Plasma taken from 22 patients with primary operable breast cancer for a prospective study of the prognostic value of the leucocyte migration inhibition test (C J Davies et al; to be published) was stored at -20°C and used in this retrospective study. The patients were divided into good and poor prognosis groups on the basis of findings on regional lymph node biopsy (low axilla, apex of axilla, and internal mammary chain) performed at simple mastectomy. The 10 patients with a good prognosis had no histological evidence of metastatic tumour in the lymph nodes. The seven with a poor prognosis had metastatic tumour in lymph nodes from the apex of the axilla or the internal mammary chain, or both. Samples taken before operation and 12 months after operation were tested in both these groups of patients. In addition preoperative samples and the last available sample before death were tested in five patients who died 10 to 22 months after operation. Ten apparently healthy age-matched women (nine hospital staff and one relative) served as controls.
Clq was purified from a pool of normal human sera by the method of Yonemasu and Stroud."1 Its purity was checked immunoelectrophoretically. Radioiodination of Clq was performed with lactoperoxidase according to the method of Heusser et al,15 giving a specific activity of about 1 tCi/pg Clq. The results described here were achieved with freshly labelled 12;I-Clq, stored no longer than two weeks at -20°C.
Plasma samples from patients and controls were stored at -20 C until tested and centrifuged at 105 000 g for 60 minutes at 4°C before use to sediment any insoluble material; the lipid layer on top of the centrifuged samples was discarded. Immune complexes were measured by the modified '2'I-Clq binding test according to the method of Zubler et al. '6 17 Briefly, 0-05 ml of unheated plasma was incubated for 30 minutes at 37°C together with 0-1 ml of 0 2-M Na2-ethylenediamine tetraacetic acid, pH 7 5, in polystyrene tubes. Thereafter 0 05 ml (0-1 slg) of '251-Clq in veronal buffered saline, pH 7 2, containing 1 % bovine serum albumin and 1 0 ml of 3 w/v polyethylene glycol molecular weight 6000 (BDH Chemicals Ltd), was added and the tubes were transferred into an ice bath. Polyethylene glycol was dissolved in borate buffered saline (0 1-M boric acid, 0 025-M disodium tetraborate, 0-075-M NaCl, pH 8-3). After the second incubation the samples were centrifuged at 1500 g for 20 minutes at 4°C and the supernatant completely discarded. Precipitated radioactivity was measured in a gamma-spectrometer (LKB, Wallac) and results were expressed as percentage '254-Clq precipitated compared with the radioactivity precipitated with trichloracetic acid (0-1 ml normal serum, 0-05 ml '25I-Clq, 1-0 ml 20% trichloracetic acid). Heataggregated human y-globulins (63°C for 20 minutes) mixed with equal amounts of normal human serum were used for positive con- Before operation all the patients with breast cancer showed high levels of immune complexes. This supports the suggestion that tumour-specific antigens are shed from the tumour into the circulation, where they evoke a specific antibody response that can be shown by methods measuring antigen-antibody complexes. Twelve months after mastectomy there were significant differences in immune complex levels between patients with a good prognosis (no evidence of dissemination to the regional lymph nodes) and both those who died within 22 months of surgery and those with a poor prognosis (extensive lymph node involvement). A possible explanation for these findings is that 12 months after excision of the primary tumour the patients with a good prognosis had insufficient residual tumour to release enough antigen for the formation of detectable quantities of immune complex. By contrast, patients expected to have considerable residual tumour may still have shed sufficient antigens to give rise to immune complex production.
Our data have several limitations. The control group did not consist of proved healthy individuals-for example, blood donors. Therefore the mean Clq binding activity in this group does not reflect an appropriate normal range-for instance, the control with Clq binding activity of 41-6°/O had suffered from jaundice.
Although two of the 10 age-matched controls showed abnormally high binding activity (greater than 20t' 0), 16 ------------------------------r ---------------------------------absorption on to tumour cell lines, low pH dissociation of active serum samples, and subsequent antibody tests or titration studies with soluble tumour extracts, since it is known that Clq binding activity decreases in antigen excess."8 In animal studies our findings and those of others' 9 show that low levels of immune complexes have to be interpreted in the light of the patient's clinical state, since a significant drop in detectable serum immune complexes occurs in animals with a large tumour burden shortly before death. This probably reflects a shift in antigen-antibody balance to high antigen excess. Thus, low levels of Clq binding activity can occur when no tumour is left or a large tumour burden is present.
